Brief: Compugen Announces FDA Clearance Of IND For COM503 For Treatment Of Solid Tumors
29/07/2024 12:15
July 29 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES FDA CLEARANCE OF IND FOR COM503 FOR THE
TREATMENT OF SOLID TUMORS
* COMPUGEN LTD - ON TRACK TO INITIATE PHASE 1 TRIAL IN Q4
2024
* COMPUGEN LTD - EXPECTS CASH RUNWAY SUFFICIENT TO TAKE US
INTO
2027
Source text for Eikon: ID:nPn5MKhmfa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025